WEBSITE BSE:543308 NSE: KIMS Inc. Year: 1973 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:54
No Notes Added Yet
1. Business Overview
Krishna Institute of Medical Sciences Ltd (KIMS) is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana, with a growing presence in Karnataka and Maharashtra. The company operates a chain of multi-specialty hospitals offering comprehensive tertiary and quaternary healthcare services. KIMS provides a wide range of medical services across specialties like cardiac sciences, oncology, neurosciences, gastric sciences, orthopedics, renal sciences, organ transplantation, and mother & child care. Its core business model revolves around providing inpatient and outpatient medical treatment, surgical procedures, diagnostics, and pharmacy services, generating revenue directly from patients, insurance companies, and government schemes.
2. Key Segments / Revenue Mix
KIMS primarily operates within the 'Hospital & Healthcare Services' industry. Its revenue is predominantly derived from its multi-specialty hospital operations. The major components of its revenue mix include:
Medical Services: Inpatient and outpatient consultations, treatments, surgeries, and procedures across various specialties.
Diagnostics: Laboratory tests, imaging services (MRI, CT scans, X-rays).
Pharmacy Sales: Revenue from in-hospital pharmacies.
While specific percentage breakdowns are not publicly available in detail, medical services constitute the bulk of its revenue.
3. Industry & Positioning
The Indian healthcare industry is characterized by significant growth, driven by an aging population, rising disposable incomes, increasing health awareness, growing prevalence of lifestyle diseases, and expanding health insurance penetration. The industry is fragmented, with both organized corporate chains and a large number of standalone hospitals and clinics. KIMS is positioned as a leading regional corporate healthcare provider, particularly strong in Andhra Pradesh and Telangana. It competes with other large national and regional hospital chains (e.g., Apollo, Fortis, Max Healthcare, Aster DM) as well as smaller local hospitals. KIMS focuses on providing quality multi-specialty care at relatively affordable price points, aiming for operational efficiency and patient volume.
4. Competitive Advantage (Moat)
Regional Scale & Brand Reputation: KIMS has established a strong brand name and significant market share in its core geographies of Andhra Pradesh and Telangana, building trust and recognition among patients and referring physicians.
Doctor Relationships: Long-standing relationships with a strong panel of experienced doctors and consultants are crucial in healthcare and contribute to patient loyalty.
Operational Efficiency: The company has demonstrated a focus on operational efficiency, which helps maintain competitive pricing and profitability.
Network Effect (within region): A growing network of hospitals within its primary operating regions allows for better patient referrals and resource optimization.
5. Growth Drivers
Increasing Demand for Healthcare: Driven by demographics (aging population, rising chronic diseases), urbanization, and growing health insurance coverage.
Expansion in Existing & New Geographies: Both brownfield (capacity expansion in existing hospitals) and greenfield (new hospital construction) expansion, along with strategic acquisitions, are key to growth. KIMS has been expanding beyond its core regions.
Medical Value Travel: India's growing appeal as a destination for medical tourism presents an opportunity for KIMS to attract international patients.
Focus on High-Value Specialties: Continued investment and strengthening of specialties like organ transplantation, oncology, and cardiac sciences that command higher revenue per patient.
Digital Health Integration: Leveraging technology for patient engagement, telemedicine, and operational efficiency.
6. Risks
Regulatory & Pricing Pressure: Government interventions like price caps on medical procedures (e.g., stents, knee implants) or Ayushman Bharat scheme tariffs can impact profitability. Changes in health insurance regulations also pose a risk.
Intense Competition: The healthcare sector is highly competitive, potentially leading to pricing pressure and challenges in attracting and retaining medical talent.
Doctor & Staff Attrition: Reliance on key medical professionals means a loss of critical doctors can impact patient volumes and reputation. Rising staff costs are also a concern.
High Capital Expenditure: Expanding the hospital network requires significant capital investment, leading to potential debt accumulation and execution risks.
Litigation & Medical Malpractice: The inherent risk of medical errors leading to legal challenges and reputational damage.
Economic Downturns: Can impact affordability for elective procedures and overall patient footfall.
7. Management & Ownership
KIMS is a promoter-led company. Dr. Bhaskar Rao, a renowned cardiothoracic surgeon, is the founder, Chairman, and Managing Director, playing a pivotal role in the company's growth and strategic direction. The management team generally comprises experienced professionals with a strong understanding of the healthcare delivery model in India. The ownership structure includes the promoter group holding a significant stake, along with institutional investors (domestic and foreign) and public shareholders. The promoter's strong medical background and long-standing experience in hospital management are key strengths.
8. Outlook
KIMS is well-positioned to capitalize on the robust growth in the Indian healthcare sector, driven by increasing demand and evolving patient needs. Its established brand equity and strong network in its core markets provide a solid foundation. The company's strategy of calibrated expansion into new geographies and focus on operational efficiency should support future growth. However, the outlook is balanced by inherent industry risks, including potential regulatory price controls, intense competition for talent and patients, and the high capital expenditure required for sustained growth. Successfully integrating new acquisitions and managing cost pressures will be crucial for maintaining its profitability and market position.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹28684 Cr.
Stock P/E 69.2
P/B 12.8
Current Price ₹716.9
Book Value ₹ 56.2
Face Value 2
52W High ₹798
Dividend Yield 0%
52W Low ₹ 575.6
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 606 | 634 | 688 | 777 | 772 | 797 | 872 | 961 | 998 | 1075 |
| Other Income | 3 | 4 | 5 | 5 | 18 | 5 | 7 | 4 | 5 | 10 |
| Total Income | 609 | 638 | 693 | 782 | 790 | 801 | 879 | 965 | 1003 | 1084 |
| Total Expenditure | 459 | 475 | 509 | 559 | 585 | 599 | 679 | 757 | 799 | 868 |
| Operating Profit | 150 | 163 | 184 | 223 | 205 | 203 | 200 | 208 | 204 | 216 |
| Interest | 12 | 16 | 18 | 20 | 26 | 27 | 33 | 45 | 57 | 68 |
| Depreciation | 35 | 46 | 39 | 41 | 45 | 53 | 53 | 66 | 79 | 85 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 11 | 0 | -0 | 0 | -11 |
| Profit Before Tax | 103 | 100 | 127 | 162 | 135 | 134 | 114 | 97 | 69 | 52 |
| Provision for Tax | 26 | 29 | 32 | 42 | 42 | 28 | 29 | 25 | 17 | 22 |
| Profit After Tax | 77 | 72 | 95 | 121 | 93 | 106 | 85 | 72 | 52 | 31 |
| Adjustments | -5 | -6 | -9 | -13 | -4 | -4 | -6 | -5 | 2 | 12 |
| Profit After Adjustments | 72 | 66 | 87 | 107 | 89 | 102 | 79 | 67 | 53 | 43 |
| Adjusted Earnings Per Share | 1.8 | 1.6 | 2.2 | 2.7 | 2.2 | 2.5 | 2 | 1.7 | 1.3 | 1.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 420 | 512 | 567 | 664 | 918 | 1123 | 1330 | 1651 | 2198 | 2498 | 3035 | 3906 |
| Other Income | 4 | 5 | 3 | 34 | 6 | 6 | 10 | 20 | 37 | 16 | 32 | 26 |
| Total Income | 424 | 516 | 570 | 698 | 924 | 1129 | 1340 | 1671 | 2235 | 2514 | 3067 | 3931 |
| Total Expenditure | 342 | 403 | 508 | 592 | 833 | 873 | 954 | 1129 | 1598 | 1854 | 2242 | 3103 |
| Operating Profit | 81 | 113 | 63 | 106 | 90 | 256 | 386 | 542 | 637 | 661 | 825 | 828 |
| Interest | 35 | 37 | 80 | 88 | 49 | 44 | 37 | 22 | 37 | 55 | 100 | 203 |
| Depreciation | 32 | 35 | 36 | 40 | 56 | 71 | 70 | 73 | 129 | 147 | 177 | 283 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 11 | -11 |
| Profit Before Tax | 14 | 41 | -53 | -22 | -15 | 141 | 279 | 457 | 485 | 460 | 558 | 332 |
| Provision for Tax | 7 | 13 | 18 | 26 | 34 | 25 | 74 | 113 | 119 | 124 | 143 | 93 |
| Profit After Tax | 7 | 28 | -71 | -48 | -49 | 115 | 205 | 344 | 366 | 336 | 415 | 240 |
| Adjustments | -2 | -1 | -0 | 1 | 1 | 4 | -4 | -11 | -29 | -26 | -30 | 3 |
| Profit After Adjustments | 6 | 27 | -71 | -47 | -48 | 119 | 201 | 333 | 336 | 310 | 385 | 242 |
| Adjusted Earnings Per Share | 0.2 | 0.8 | -2.8 | -1.9 | -1.3 | 3.2 | 5.2 | 8.3 | 8.4 | 7.8 | 9.6 | 6.1 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 21% | 23% | 22% | 22% |
| Operating Profit CAGR | 25% | 15% | 26% | 26% |
| PAT CAGR | 24% | 6% | 29% | 50% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 11% | 33% | NA% | NA% |
| ROE Average | 21% | 21% | 25% | 3% |
| ROCE Average | 19% | 22% | 27% | 18% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 238 | 263 | -113 | -158 | 541 | 598 | 864 | 1387 | 1670 | 1828 | 2138 |
| Minority's Interest | 6 | 7 | 5 | 21 | 25 | 13 | 12 | 23 | 268 | 265 | 281 |
| Borrowings | 201 | 174 | 199 | 249 | 243 | 269 | 185 | 138 | 497 | 928 | 1654 |
| Other Non-Current Liabilities | 42 | 47 | 45 | 53 | 104 | 96 | 94 | 141 | 169 | 347 | 767 |
| Total Current Liabilities | 170 | 174 | 629 | 745 | 201 | 219 | 278 | 215 | 296 | 452 | 836 |
| Total Liabilities | 657 | 665 | 764 | 910 | 1114 | 1194 | 1433 | 1904 | 2901 | 3820 | 5676 |
| Fixed Assets | 511 | 515 | 523 | 711 | 863 | 916 | 931 | 1005 | 1766 | 2434 | 3349 |
| Other Non-Current Assets | 46 | 35 | 96 | 43 | 77 | 59 | 51 | 506 | 657 | 839 | 1630 |
| Total Current Assets | 101 | 115 | 146 | 156 | 174 | 220 | 451 | 393 | 478 | 547 | 697 |
| Total Assets | 657 | 665 | 764 | 910 | 1114 | 1194 | 1433 | 1904 | 2901 | 3820 | 5676 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 9 | 14 | 3 | 8 | 11 | 8 | 41 | 52 | 26 | 62 | 47 |
| Cash Flow from Operating Activities | 64 | 95 | 83 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 |
| Cash Flow from Investing Activities | -71 | -41 | -70 | -64 | -110 | -125 | -354 | -412 | -547 | -753 | -1116 |
| Cash Flow from Financing Activities | 12 | -65 | -8 | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 |
| Net Cash Inflow / Outflow | 5 | -11 | 5 | 3 | -3 | 32 | 12 | -26 | -95 | -15 | 9 |
| Closing Cash & Cash Equivalent | 14 | 3 | 8 | 11 | 8 | 41 | 52 | 26 | 62 | 47 | 56 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.16 | 0.76 | -2.84 | -1.88 | -1.28 | 3.2 | 5.19 | 8.31 | 8.41 | 7.75 | 9.61 |
| CEPS(Rs) | 1.12 | 1.8 | -1.39 | -0.32 | 0.2 | 4.99 | 7.09 | 10.41 | 12.37 | 12.06 | 14.8 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 6.77 | 7.48 | -4.51 | -6.31 | 14.51 | 16.05 | 22.26 | 34.67 | 41.72 | 45.71 | 53.45 |
| Core EBITDA Margin(%) | 18.41 | 21.27 | 10.49 | 10.76 | 9.22 | 22.22 | 28.25 | 31.6 | 27.27 | 25.81 | 26.13 |
| EBIT Margin(%) | 11.72 | 15.23 | 4.73 | 9.97 | 3.74 | 16.48 | 23.79 | 29 | 23.76 | 20.57 | 21.7 |
| Pre Tax Margin(%) | 3.37 | 7.99 | -9.33 | -3.31 | -1.64 | 12.52 | 20.98 | 27.67 | 22.06 | 18.39 | 18.39 |
| PAT Margin (%) | 1.72 | 5.47 | -12.48 | -7.2 | -5.29 | 10.25 | 15.45 | 20.83 | 16.65 | 13.45 | 13.67 |
| Cash Profit Margin (%) | 9.4 | 12.4 | -6.14 | -1.23 | 0.82 | 16.54 | 20.68 | 25.23 | 22.53 | 19.31 | 19.51 |
| ROA(%) | 1.11 | 4.23 | -9.91 | -5.71 | -4.8 | 9.97 | 15.64 | 20.6 | 15.23 | 10 | 8.74 |
| ROE(%) | 3.31 | 11.15 | -94.27 | 0 | -25.44 | 20.22 | 28.12 | 30.55 | 23.93 | 19.21 | 20.92 |
| ROCE(%) | 9.91 | 14.96 | 5.18 | 12.42 | 4.99 | 21.17 | 30.82 | 35.69 | 27.84 | 20.25 | 19.04 |
| Receivable days | 29.46 | 37.01 | 47.56 | 51.94 | 45.88 | 41.54 | 33.22 | 26.36 | 31.66 | 39.96 | 41.48 |
| Inventory Days | 9.93 | 8.4 | 9.24 | 10.05 | 9.34 | 9.3 | 7.47 | 6.69 | 6.58 | 6.74 | 6.82 |
| Payable days | 199.08 | 186.41 | 192.4 | 196.7 | 172.78 | 163.35 | 161.26 | 134.33 | 115.35 | 127.64 | 135.6 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 33.2 | 33.46 | 53.11 | 66.51 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.96 | 6.74 | 9.01 | 11.96 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.67 | 0.62 | 1.18 | 1.12 | 0.38 | 0.31 | 0.05 | 6.67 | 5.33 | 6.99 | 9.03 |
| EV/Core EBITDA(x) | 3.43 | 2.81 | 10.69 | 7.05 | 3.89 | 1.37 | 0.16 | 20.33 | 18.41 | 26.43 | 33.21 |
| Net Sales Growth(%) | 19.56 | 21.95 | 10.81 | 17.02 | 38.32 | 22.29 | 18.46 | 24.13 | 33.13 | 13.67 | 21.49 |
| EBIT Growth(%) | 4.4 | 58.49 | -65.61 | 146.73 | -48.04 | 438.28 | 71.03 | 51.33 | 9.08 | -1.57 | 28.11 |
| PAT Growth(%) | 29.18 | 288.58 | -353.08 | 32.49 | -1.66 | 336.84 | 78.57 | 67.31 | 6.4 | -8.18 | 23.49 |
| EPS Growth(%) | -6.46 | 374.56 | -475.97 | 33.83 | 31.98 | 350.09 | 62.08 | 60.3 | 1.09 | -7.79 | 24.03 |
| Debt/Equity(x) | 1.19 | 0.97 | -5.56 | -4.47 | 0.53 | 0.54 | 0.31 | 0.12 | 0.32 | 0.57 | 0.89 |
| Current Ratio(x) | 0.59 | 0.66 | 0.23 | 0.21 | 0.87 | 1 | 1.62 | 1.83 | 1.61 | 1.21 | 0.83 |
| Quick Ratio(x) | 0.53 | 0.59 | 0.21 | 0.18 | 0.73 | 0.87 | 1.53 | 1.66 | 1.47 | 1.1 | 0.76 |
| Interest Cover(x) | 1.4 | 2.1 | 0.34 | 0.75 | 0.7 | 4.16 | 8.47 | 21.89 | 14.01 | 9.43 | 6.56 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.05 | 0.06 | 0.07 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 38.82 | 38.82 | 38.82 | 38.82 | 38.82 | 38.82 | 34.11 | 34.11 | 34.11 | 34.11 |
| FII | 15.27 | 16.73 | 17.84 | 15.85 | 15.68 | 15.45 | 15.54 | 15.03 | 14.33 | 14.57 |
| DII | 34.23 | 33.13 | 32.12 | 32.3 | 32.05 | 31.95 | 31.65 | 32.12 | 32.61 | 32.38 |
| Public | 11.68 | 11.32 | 11.22 | 13.03 | 13.45 | 13.78 | 18.69 | 18.75 | 18.95 | 18.94 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 3.11 | 3.11 | 3.11 | 15.53 | 15.53 | 15.53 | 13.65 | 13.65 | 13.65 | 13.65 |
| FII | 1.22 | 1.34 | 1.43 | 6.34 | 6.28 | 6.18 | 6.22 | 6.01 | 5.73 | 5.83 |
| DII | 2.74 | 2.65 | 2.57 | 12.92 | 12.82 | 12.79 | 12.67 | 12.85 | 13.05 | 12.96 |
| Public | 0.93 | 0.91 | 0.9 | 5.21 | 5.38 | 5.51 | 7.48 | 7.5 | 7.58 | 7.58 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 40.01 | 40.01 | 40.01 | 40.01 | 40.01 | 40.01 | 40.01 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.